Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 3/20 | 0.73 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.73 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.73 |
| ▸ | PTGIR | P43119 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10742477 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL11079261 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL3368201 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL29424279 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL29420457 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL23352779 | 1.00 | PTGFR (0.73) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| SCHEMBL11379818 | 0.91 | PTGER4 (0.70) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| Trimoprostil SCHEMBL11024670 | 0.91 | PTGER3 (0.64) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| Trimoprostil SCHEMBL564049 | 0.91 | PTGER3 (0.64) | PTGFRPTGER3PTGER4PTGER2PTGIR | |
| Trimoprostil SCHEMBL11226793 | 0.91 | PTGER3 (0.64) | PTGFRPTGER3PTGER4PTGER2PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533362-B2 | Methods for treating diseases associated with ciliopathies | ALEXION PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | claimed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | claimed |
| CN-118681021-A | Composition for treating androgenetic alopecia | 徐春禄 | 2024-09-24 | — | — | CN | claimed |
| CN-118453877-A | Application of small molecular compound combination in preparing medicine for starting liver in-situ regeneration | 中国人民解放军海军军医大学 | 2024-08-09 | — | — | CN | claimed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | claimed |
| EP-4151720-B1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | BLUEBIRD BIO INC (US) | 2024-08-07 | — | — | EP | claimed |
| CN-111212648-B | Compositions and methods for preventing or treating muscle disorders | 莱兰斯坦福初级大学评议会 | 2024-07-09 | — | — | CN | claimed |
| US-20240207402-A1 | MEANS AND METHODS FOR ENHANCING RECEPTOR-TARGETED GENE TRANSFER | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2024-06-27 | — | — | US | claimed |
| EP-4320244-A1 | MEANS AND METHODS FOR ENHANCING RECEPTOR-TARGETED GENE TRANSFER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2024-02-14 | — | — | EP | claimed |
| CN-117018195-A | Application of small molecular compound or combination in preparation of medicine for starting liver in-situ regeneration | 中国人民解放军海军军医大学 | 2023-11-10 | — | — | CN | claimed |
| EP-0089768-B1 | COMPOSITIONS CONTAINING PROSTAGLANDINS | UPJOHN LIMITED (GB) | 1990-09-26 | — | — | EP | claimed |
| EP-0116358-B1 | COMPLEXES OF PROSTAGLANDINS | BAYER AG (DE) | 1988-04-27 | — | — | EP | claimed |
| EP-0106649-B1 | PROSTAGLANDINS AND THEIR USE | THE UPJOHN COMPANY (US) | 1987-08-12 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| EP-0055593-B1 | COMPOSITIONS COMPRISING E-PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| EP-0106649-A2 | Prostaglandins and their use | THE UPJOHN COMPANY (US) | 1984-04-25 | — | — | EP | claimed |
| EP-0089768-A1 | Compositions containing prostaglandins | UPJOHN LIMITED (GB) | 1983-09-28 | — | — | EP | claimed |
| EP-0055593-A2 | Compositions comprising E-prostaglandins | THE UPJOHN COMPANY (US) | 1982-07-07 | — | — | EP | claimed |
| WO-1980001985-A1 | CONTROLLED RELEASE COMPOSITIONS (II) | EMBREY M (GB) | 1980-10-02 | — | — | WO | claimed |
| EP-0016654-A1 | Composition for the controlled release of a prostaglandine and process for its preparation | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1980-10-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533362-B2 | Methods for treating diseases associated with ciliopathies | PKD2, PKD1, SHH | PTGFR 94/4885PTGER3 98/4885PTGER4 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.